3,206,271 Shares in Urogen Pharma $URGN Purchased by RA Capital Management L.P.

Key Points

• RA Capital Management L.P. has acquired 3,206,271 shares of Urogen Pharma, representing approximately 6.95% ownership, valued at around $35.5 million.
• Urogen Pharma recently reported a significant quarterly loss with an EPS of ($1.05), missing analysts' expectations, despite a revenue of $24.22 million.
• Analysts show varied responses towards Urogen's stock, with price targets ranging from $16.00 to $31.00, and a general rating of “Buy” from most brokerages.

RA Capital Management L.P. purchased a new stake in Urogen Pharma (NASDAQ:URGN - Free Report) during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm purchased 3,206,271 shares of the company's stock, valued at approximately $35,461,000. RA Capital Management L.P. owned approximately 6.95% of Urogen Pharma at the end of the most recent quarter.

Other hedge funds also recently made changes to their positions in the company. CWM LLC boosted its stake in shares of Urogen Pharma by 6,047.1% in the 1st quarter. CWM LLC now owns 5,225 shares of the company's stock valued at $58,000 after purchasing an additional 5,140 shares in the last quarter. Lazard Asset Management LLC acquired a new stake in Urogen Pharma during the 4th quarter worth approximately $67,000. GAMMA Investing LLC boosted its position in Urogen Pharma by 6,908.4% during the 1st quarter. GAMMA Investing LLC now owns 7,499 shares of the company's stock worth $83,000 after buying an additional 7,392 shares during the period. Aquatic Capital Management LLC acquired a new stake in Urogen Pharma during the 4th quarter worth approximately $101,000. Finally, ProShare Advisors LLC acquired a new stake in Urogen Pharma during the 4th quarter worth approximately $137,000. 91.29% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several equities research analysts recently commented on the stock. Piper Sandler assumed coverage on shares of Urogen Pharma in a research report on Monday, August 18th. They set an "overweight" rating and a $36.00 target price on the stock. HC Wainwright dropped their price target on shares of Urogen Pharma from $50.00 to $40.00 and set a "buy" rating on the stock in a research report on Monday, August 11th. D. Boral Capital restated a "buy" rating and issued a $25.00 price target on shares of Urogen Pharma in a research report on Tuesday, August 5th. Guggenheim restated a "buy" rating and issued a $30.00 price target (up previously from $15.00) on shares of Urogen Pharma in a research report on Friday, June 13th. Finally, The Goldman Sachs Group set a $16.00 price target on shares of Urogen Pharma and gave the stock a "neutral" rating in a research report on Friday, June 13th. One investment analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating and one has assigned a Hold rating to the stock. According to data from MarketBeat, the company presently has an average rating of "Buy" and an average price target of $32.00.

Insiders Place Their Bets

In other news, insider Mark Schoenberg sold 10,000 shares of the company's stock in a transaction on Monday, August 11th. The shares were sold at an average price of $17.69, for a total value of $176,900.00. Following the completion of the sale, the insider owned 148,229 shares in the company, valued at $2,622,171.01. This represents a 6.32% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, General Counsel Jason Drew Smith sold 7,522 shares of the company's stock in a transaction on Monday, July 28th. The stock was sold at an average price of $19.14, for a total transaction of $143,971.08. Following the completion of the sale, the general counsel owned 41,492 shares of the company's stock, valued at approximately $794,156.88. The trade was a 15.35% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 27,833 shares of company stock valued at $457,467 in the last 90 days. 4.70% of the stock is currently owned by company insiders.

Urogen Pharma Stock Up 0.4%

URGN stock traded up $0.08 during midday trading on Friday, reaching $18.88. 1,029,077 shares of the company's stock traded hands, compared to its average volume of 1,527,646. The company has a market cap of $873.39 million, a price-to-earnings ratio of -5.69 and a beta of 1.10. The firm's fifty day moving average price is $17.54 and its 200-day moving average price is $12.52. Urogen Pharma has a 52 week low of $3.42 and a 52 week high of $21.01.

Urogen Pharma (NASDAQ:URGN - Get Free Report) last announced its quarterly earnings results on Thursday, August 7th. The company reported ($1.05) EPS for the quarter, missing analysts' consensus estimates of ($0.82) by ($0.23). The business had revenue of $24.22 million for the quarter, compared to the consensus estimate of $23.06 million. Urogen Pharma had a negative net margin of 164.44% and a negative return on equity of 97,487.15%. Analysts forecast that Urogen Pharma will post -3.12 earnings per share for the current year.

Urogen Pharma Company Profile

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution.